[In vitro activity of carbapenems (biapenem, imipenem and meropenem) and some other antibiotics against strict anaerobic bacteria]. 1995

S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
Centre Hospitalier, Annecy, France.

During 1994, the in vitro antibiotic susceptibility of 306 anaerobic bacteria was performed in 4 hospitals, by the reference agar dilution method. Among the 129 B. fragilis group strains, only two B. fragilis strains were resistant to the three carbapenems and all beta-lactams, even combined with beta-lactamase-inhibitors while metronidazole resistance could not be detected. Evolution in antibiotic resistance rates could be assessed only for piperacillin whose resistance rates increased to 20%. beta-lactamase production was detected respectively for 27% of Prevotella and 17% of Fusobacterium strains. No beta-lactamase activity was seen among Gram positive anaerobes. On the whole anaerobic strains resistance rates were: biapenem, imipenem, meropenem and piperacillin-tazobactam 0.7, amoxicillin-clavulanic acid or metronidazole 2, piperacillin 11.3, amoxicillin 31%, respectively. The three carbapenems demonstrated a good in vitro activity against most anaerobes with few differences between them.

UI MeSH Term Description Entries
D010462 Peptostreptococcus A genus of gram-positive, anaerobic, coccoid bacteria that is part of the normal flora of humans. Its organisms are opportunistic pathogens causing bacteremias and soft tissue infections.
D003013 Clostridium A genus of motile or nonmotile gram-positive bacteria of the family Clostridiaceae. Many species have been identified with some being pathogenic. They occur in water, soil, and in the intestinal tract of humans and lower animals.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005051 Eubacterium A genus of gram-positive, rod-shaped bacteria found in cavities of man and animals, animal and plant products, infections of soft tissue, and soil. Some species may be pathogenic. No endospores are produced. The genus Eubacterium should not be confused with EUBACTERIA, one of the three domains of life. Butyribacterium
D005673 Fusobacterium A genus of gram-negative, anaerobic, rod-shaped bacteria found in cavities of humans and other animals. No endospores are formed. Some species are pathogenic and occur in various purulent or gangrenous infections. Sphaerophorus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077731 Meropenem A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients. 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid,Merrem,Penem,Ronem,SM 7338,SM-7338,SM7338
D001441 Bacteroides fragilis Gram-negative bacteria occurring in the lower intestinal tracts of man and other animals. It is the most common species of anaerobic bacteria isolated from human soft tissue infections.
D013845 Thienamycins Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors. Antibiotics, Thienamycin,Thienamycin Antibiotics
D015378 Imipenem Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor. Imipemide,N-Formimidoylthienamycin,Imipenem Anhydrous,Imipenem, Anhydrous,MK-0787,MK0787,Anhydrous Imipenem,Anhydrous, Imipenem,MK 0787,N Formimidoylthienamycin

Related Publications

S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
January 1990, Diagnostic microbiology and infectious disease,
S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
October 1984, European journal of clinical microbiology,
S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
January 1985, Reviews of infectious diseases,
S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
January 1993, Diagnostic microbiology and infectious disease,
S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
July 1989, Journal of chemotherapy (Florence, Italy),
S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
January 1987, International journal of clinical pharmacology research,
S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
April 1995, Toxicology letters,
S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
February 2022, Antibiotics (Basel, Switzerland),
S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
January 1992, Chemotherapy,
S Bland, and A Sedallian, and G Grollier, and F Mory, and I Houcke, and L Dubreuil
May 1994, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!